Xanthomatous Dermal Changes in a Patient With Locally Advanced Basal Cell Carcinoma Treated Using Vismodegib. (August 2021)

• Record Type: Journal Article
• Authors: Smith, Shane D. B.; Clarke, Callisia N.; Clark, Melanie A.; Harker-Murray, Amy K.; Sokumbi, Olayemi
• Is Part Of: American journal of dermatopathology. Volume 43:Number 8(2021)
• Publication Date: 2021-08
• Subjects: vismodegib -- basal cell carcinoma -- xanthomatous changes; Skin -- Diseases -- Periodicals; Histology, Pathological -- Periodicals; 616.50705
• DOI: 10.1097/DAD.0000000000001849
• Languages: English
• ISSNs: 0193-1091

Abstract

Abstract : Abstract: Basal cell carcinoma (BCC) is the most commonly diagnosed cutaneous cancer in the United States with more than 2.5 million treated annually. Genetic studies have revealed that approximately 90% of BCCs have a mutation in the hedgehog-signaling pathway. Patients with BCC usually have an excellent prognosis with surgical modalities, however, patients with locally advanced BCC may potentially experience significant cosmetic or functional impairment, with only surgical intervention. Vismodegib is a hedgehog pathway inhibitor that has been successful in treating patients with locally advanced BCC. We report a patient with BCC with a good response to vismodegib and a novel xanthomatous change in the excision specimen.